TRAVATAN – Travoprost

Travatan Eye Drop Used For

Travatan is used to treat certain kinds of glaucoma. It is also used to treat a condition called hypertension of the eye. Travatan appears to work by increasing the outflow of fluid from the eye. This lowers the pressure in the eye.

Directions for Travatan Eye Drop

The recommended dosage is one drop in the affected eye(s) once-daily in the evening. The dosage of Travatan should not exceed once-daily since it frequent administration may decrease its effectiveness. Travatan may be used concomitantly with other topical ophthalmic drug products to lower intraocular pressure. If more than one topical ophthalmic drug is being used, the drugs should be administered at least five (5) minutes apart.

How Travatan Eye Drop works

Travatan should not be prescribed for patients with known allergies to travoprost since this my lead to itching, redness, swelling, or other signs of eye or eyelid irritation occur. This medicine may also cause some people to have blurred vision for a short time after each use. It is advisable to avoid driving, using machines or anything else that might be dangerous for you while having blurred vision. If you miss a dose of this medicine, use it as soon as you remember. However, if it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not double doses.

Travatan medication Side effects

Travatan might cause changes in pigmented tissues with the most frequent reports being changes and increased pigmentation of the iris and the periorbital tissue (eyelid) as well as pigmentation and growth of eyelashes. These changes may be permanent. The change in iris color occurs slowly and may not be noticeable for months to years. Patients should be informed of the possibility of iris color change.

Other Travatan Eye Drop Information

Reduction of intraocular pressure starts approximately 2 hours after administration of Travatan and the maximum effect is reached after about 12 hours. Patients who are expected to receive treatment in only one eye should be informed about the potential for pigmentation of the iris, periorbital and/or eyelid tissue, and eyelashes in the treated eye and thus heterochromia between the eyes. They should also be advised of the potential for a disparity between the eyes in length, thickness, and/or number of eyelashes.